
CHIR-99021 trihydrochloride
CAS No. 1782235-14-6
CHIR-99021 trihydrochloride( CT99021 trihydrochloride | CHIR99021 trihydrochloride | CHIR 99021 trihydrochloride | CT-99021 trihydrochloride )
Catalog No. M12681 CAS No. 1782235-14-6
A potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 47 | Get Quote |
![]() ![]() |
5MG | 77 | Get Quote |
![]() ![]() |
10MG | 124 | Get Quote |
![]() ![]() |
25MG | 255 | Get Quote |
![]() ![]() |
50MG | 482 | Get Quote |
![]() ![]() |
100MG | 646 | Get Quote |
![]() ![]() |
500MG | 1341 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCHIR-99021 trihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively.
-
DescriptionA potent, specific GSK-3 inhibitor with IC50 of 5 nM and 10 nM for GSK3β and GSK3α, respectively; mimics Wnt signaling in preadipocytes, stabilizes free cytosolic beta-catenin and inhibits adipogenesis by blocking induction of C/EBPα and PPARγ; potentiates insulin activation of glucose transport and utilization in vitro and in vivo; also widely used for stem cell differentiation and naive stem cell generation.
-
In VitroLaduviglusib trihydrochloride inhibits human GSK-3β with Ki values of 9.8 nM. Laduviglusib trihydrochloride is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib trihydrochloride specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases. In the presence of Laduviglusib trihydrochloride the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib trihydrochloride with an IC50 of 4.9 μM.
-
In VivoIn ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) trihydrochloride rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration. Laduviglusib (2 mg/kg) trihydrochloride given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib trihydrochloride treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib trihydrochloride treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h.
-
SynonymsCT99021 trihydrochloride | CHIR99021 trihydrochloride | CHIR 99021 trihydrochloride | CT-99021 trihydrochloride
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1782235-14-6
-
Formula Weight574.7208
-
Molecular FormulaC22H21Cl5N8
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESCC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N.Cl.Cl.Cl
-
Chemical Name3-Pyridinecarbonitrile, 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-, hydrochloride (1:3)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ying QL, et al. Nature. 2008 May 22;453(7194):519-23.
2. Ring DB, et al. Diabetes. 2003 Mar;52(3):588-95.
3. Bennett CN, et al. J Biol Chem. 2002 Aug 23;277(34):30998-1004.
4. Li W, et al. Stem Cells. 2009 Dec;27(12):2992-3000.
molnova catalog



related products
-
GSK3a-IN-38
GSK3a-IN-38 is a novel small molecule compound that has inhibitory effects on GSK-3a.
-
GSK-3β inhibitor 12
GSK-3β inhibitor 12 is a selective GSK-3β inhibitor.GSK-3β inhibitor 12 inhibits 49.11% of 25 μM GSK-3β activity and 37.11% of 50 μM GSK-3β activity.
-
BRD0209
BRD0209 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 19 nM/5 nM for GSK3α/GSK3β respectively.